血管イメージング市場規模、シェア、動向、2030年までの世界予測

血管イメージング市場 – 技術（MRI、超音波、CT、ハイブリッド、OCT）、用途（動脈硬化症、深部静脈血栓症、血管炎、動脈瘤性疾患、動静脈奇形、腫瘍、その他）、エンドユーザー（病院、診断画像センター） – 2030年までの世界予測

世界の血管イメージング市場は、2025年の31億9,000万米ドルから2030年には45億4,000万米ドルに達すると予測されており、予測期間中は年平均成長率（CAGR）7.3%で成長します。血管イメージング市場の成長は、心血管疾患の負担増加、早期かつ正確な診断の必要性、そして血管疾患に罹患しやすい高齢者人口の増加によって促進されています。3Dイメージング、AIを活用した診断、非侵襲的手法といった技術の進歩は、精度と効率性を向上させ、導入拡大を促進しています。さらに、特に新興国における医療投資の増加、インフラの改善、そして予防医療への重点化も、市場の拡大に大きく貢献しています。
血管イメージング市場は、製品タイプ、用途、エンドユーザー、地域別にセグメント化されています。市場の成長に影響を与える主な要因には、推進力、制約、機会、そしてステークホルダーにとっての課題が含まれます。本レポートでは、血管イメージング市場で競合する主要企業についても分析しています。ミクロレベルの分析を行うことで、トレンド、成長機会、そして市場への貢献を分析できます。さらに、5つの主要地域における様々な市場セグメントにおける潜在的な収益成長機会についても明らかにしています。

本レポートは、血管イメージング市場への新規参入企業にとって、市場に関する包括的な情報を提供するため、非常に有益です。この情報は、様々な投資機会を理解する上で不可欠です。本レポートは、市場における主要企業と小規模企業の両方に関する洞察を提供し、投資判断を行う際のリスク分析の確固たる基盤の構築に役立ちます。また、エンドユーザーと地域別に市場を正確にセグメント化し、特定の市場セグメントに的を絞った洞察を提供しています。さらに、主要なトレンド、課題、成長要因、そして機会を網羅し、徹底的な分析を通じて戦略的意思決定を支援します。

本レポートは、以下の点について洞察を提供しています。

血管イメージング市場の成長を牽引する主な要因（心血管疾患の有病率の上昇、低侵襲性および個別化医療介入、血管イメージング技術の進歩、官民連携組織による投資、資金、助成金の増加）、制約要因（放射線被ばくおよび造影剤関連リスク、不利な償還シナリオ、高額な費用とリソース要件）、機会（経済成長による高い成長ポテンシャル、病院および診断用画像センターの設立増加、遠隔放射線診断の導入増加）、そして課題（病院予算の削減、再生診断用画像システムの導入増加、訓練を受けた専門家の不足、患者および生理的動きによる画質の限界）

• 製品開発／イノベーション：宇宙分野における新興技術、研究開発、血管イメージング市場における最近の製品の発売および承認。
• 市場成長：収益性の高い市場に関する詳細な洞察に基づき、様々な地域における血管イメージング市場を分析します。
• 市場多様化：血管イメージング市場における新製品、未開拓地域、最新トレンド、投資に関する詳細な分析。
• 競合評価：フィリップス・ヘルスケア（オランダ）、GEヘルスケア（米国）、キヤノンメディカルシステムズ株式会社（日本）、シーメンス・ヘルシニアーズ（ドイツ）、富士フイルム株式会社（日本）など、主要企業の市場シェア、サービス内容、主要戦略に関する詳細な評価。

Report Description

The global vascular imaging market is projected to reach USD 4.54 billion by 2030 from USD 3.19 billion in 2025, growing at a CAGR of 7.3% during the forecast period. The growth in the vascular imaging market is fueled by the increasing burden of cardiovascular diseases, the need for early and precise diagnosis, and the expanding elderly population vulnerable to vascular conditions. Advances in technology, including 3D imaging, AI-powered diagnostics, and non-invasive techniques, are enhancing accuracy and efficiency, driving wider adoption. Furthermore, rising healthcare investments, improved infrastructure, and greater emphasis on preventive care, especially across emerging economies, are contributing significantly to the market’s expansion.

By product type, the systems & consoles segment is expected to register the highest CAGR during the forecast period.

By product type, the systems & consoles segment is expected to account for the highest CAGR in the vascular imaging market because they serve as the core platforms enabling advanced imaging modalities such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), and near-infrared spectroscopy (NIRS). These systems provide high-resolution, real-time visualization critical for accurate diagnosis and guided interventions, driving demand in hospitals, ambulatory surgery centers, and specialty clinics. Continuous technological innovations—such as integration with AI, enhanced imaging software, and hybrid imaging capabilities—boost their clinical utility and adoption. Additionally, recurring revenue from compatible catheters and accessories further propels market growth, making systems and consoles a key investment focus for manufacturers.

By application, the vasculitis segment accounted for the highest CAGR of the market in 2024.

In the vascular imaging market, the vasculitis segment dominated the market due to its increasing prevalence and the critical need for accurate diagnosis and monitoring of inflammation in blood vessels. Advances in imaging technologies such as PET, MRI, and CT angiography have significantly improved the ability to detect and assess vasculitis at early stages, enabling timely and targeted treatment. Additionally, growing awareness among clinicians about the importance of vascular imaging in managing vasculitis, coupled with rising investment in advanced imaging modalities, is accelerating market growth. The chronic nature of vasculitis and its potential to cause severe complications further underscores the demand for sophisticated vascular imaging solutions, fueling robust expansion in this segment.

Asia Pacific is expected to register the highest growth rate in the market during the forecast period.

The Asia-Pacific region is expected to register the highest CAGR in the vascular imaging market, driven by the growing burden of cardiovascular diseases linked to an aging population, sedentary lifestyles, and the increasing prevalence of diabetes and hypertension. Significant investments in healthcare infrastructure, government programs promoting early diagnosis, and the rapid adoption of advanced imaging technologies are further fueling demand. Additionally, rising healthcare spending, the need for affordable imaging solutions, and the integration of AI-based tools across major economies such as China and India are propelling the region’s strong market growth.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level Executives (55%), Directors (27%), and Others (18%)

By Region: North America (35%), Europe (32%), Asia Pacific (25%), Latin America (6%), and the Middle East & Africa (2%)

The prominent players in this market are Philips Healthcare (Netherlands), GE Healthcare (US), Canon Medical Systems Corporation (Japan), Siemens Healthineers (Germany), Shenzhen Mindray Bio-Medical Electronics (China), FUJIFILM Corporation (Japan), Hologic Inc. (US), Samsung Electronics Co., Ltd. (South Korea), Shimadzu Corporation (Japan), United Imaging Healthcare (China), Konica Minolta (Japan), Neusoft Corporation (China), Bracco Imaging SPA (Italy), Bayer AG (Germany), Guerbet (France), Nipro Europe Group Companies (Belgium).

Research Coverage

The vascular imaging market is segmented by product type, application, end user, and region. Key factors influencing market growth include driving forces, restraints, opportunities, and challenges for stakeholders. The report also reviews the leading companies competing in the Vascular imaging market. A micro-level analysis can be conducted to examine trends, growth opportunities, and contributions to the market. Additionally, it highlights potential revenue growth opportunities across various market segments in five major regions.

Key Benefits of Buying the Report

The report is valuable for new entrants in the vascular imaging market as it provides comprehensive information about the market. This information is essential for understanding various investment opportunities. The report provides insights into both key and smaller players in the market, which can help create a solid basis for risk analysis when making investment decisions. It accurately segments the market by end users and regions, providing focused insights into specific market segments. Additionally, the report highlights key trends, challenges, growth drivers, and opportunities to support strategic decision-making through a thorough analysis.

The report provides insights into the following points:

• Key drivers (rising prevalence of cardiovascular diseases, minimally invasive and personalized interventions, technological advancements in vascular imaging technology, increasing investments, funds, and grants by public-private organizations), restraints (radiation exposure and contrast-related risks, unfavorable reimbursement scenario, high costs and resource requirements), opportunities (expanding economies offer high growth potential, increasing establishment of hospitals and diagnostic imaging centers, increasing adoption of teleradiology), and challenges (hospital budget cuts, increasing adoption of refurbished diagnostic imaging systems, dearth of trained professionals, image quality limitations because of patient and physiological motion) fueling the market growth of vascular imaging market.
• Product Development/Innovation: Emerging technologies in space, R&D, recent product launches & approvals in the vascular imaging market.
• Market Growth: In-depth insights into remunerative markets report analyze the vascular imaging market across varied geographies.
• Market Diversification: Detailed analysis of new products, unexplored geographies, latest trends, and investments in the vascular imaging market
• Competitive Assessment: Detailed assessment of market share, service offerings, leading strategies of key players such as Philips Healthcare (Netherlands), GE Healthcare (US), Canon Medical Systems Corporation (Japan), Siemens Healthineers (Germany), and FUJIFILM Corporation (Japan), among others.

Table of Contents

1               INTRODUCTION              26

1.1           STUDY OBJECTIVES       26

1.2           MARKET DEFINITION   26

1.3           STUDY SCOPE   27

1.3.1        MARKET SEGMENTATION AND REGIONAL SCOPE                 27

1.3.2        INCLUSIONS AND EXCLUSIONS 27

1.3.3        YEARS CONSIDERED      28

1.4           CURRENCY CONSIDERED            28

1.5           STAKEHOLDERS               28

2               RESEARCH METHODOLOGY       29

2.1           RESEARCH DATA              29

2.1.1        SECONDARY RESEARCH                29

2.1.1.1    Key data from secondary sources       31

2.1.2        PRIMARY RESEARCH       31

2.1.2.1    Key industry insights           33

2.2           MARKET SIZE ESTIMATION APPROACH 34

2.2.1        APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH         36

2.2.2        APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION     37

2.3           MARKET FORECASTING                39

2.4           DATA TRIANGULATION AND MARKET BREAKDOWN                 40

2.5           MARKET SHARE ASSESSMENT   40

2.6           RESEARCH ASSUMPTIONS           41

2.7           RESEARCH LIMITATIONS             41

2.8           RISK ANALYSIS  41

3               EXECUTIVE SUMMARY  42

4               PREMIUM INSIGHTS       45

4.1           VASCULAR IMAGING MARKET OVERVIEW            45

4.2           NORTH AMERICA: VASCULAR IMAGING MARKET, BY COUNTRY AND END USER, 2025                 46

4.3           GEOGRAPHIC SNAPSHOT OF VASCULAR IMAGING MARKET               47

5               MARKET OVERVIEW       48

5.1           INTRODUCTION              48

5.2           MARKET DYNAMICS       48

5.2.1        DRIVERS               49

5.2.1.1    Rising prevalence of cardiovascular diseases   49

5.2.1.2    Growing inclination toward minimally invasive and personalized interventions          49

5.2.1.3    Technological advancements in vascular imaging systems                 50

5.2.1.4    Increasing investments, funds, and grants by public-private organizations         51

5.2.2        RESTRAINTS      52

5.2.2.1    High cost and resource requirements                52

5.2.2.2    Radiation exposure and contrast-related risks 52

5.2.2.3    Unfavorable reimbursement scenario                52

5.2.3        OPPORTUNITIES              53

5.2.3.1    High growth potential in emerging economies                53

5.2.3.2    Increasing establishment of hospitals and diagnostic imaging centers    53

5.2.3.3    Rising adoption of teleradiology         54

5.2.4        CHALLENGES    55

5.2.4.1    Need to maintain high-quality, artifact-free images       55

5.2.4.2    Hospital budget cuts            55

5.2.4.3    Increasing adoption of refurbished vascular imaging systems                 55

5.2.4.4    Dearth of trained professionals          56

5.3           UNMET NEEDS 56

5.4           INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES              57

5.5           STRATEGIC MOVES BY TIER 1/2/3 PLAYERS         57

6               INDUSTRY TRENDS         59

6.1           PORTER’S FIVE FORCES ANALYSIS           59

6.1.1        BARGAINING POWER OF BUYERS             60

6.1.2        BARGAINING POWER OF SUPPLIERS       60

6.1.3        THREAT OF NEW ENTRANTS      60

6.1.4        THREAT OF SUBSTITUTES          60

6.1.5        INTENSITY OF COMPETITIVE RIVALRY 60

6.2           MACROECONOMIC INDICATORS              61

6.2.1        INTRODUCTION              61

6.2.2        GDP TRENDS AND FORECAST   61

6.2.3        TRENDS IN GLOBAL ENVIRONMENTAL INDUSTRY                 61

6.2.4        TRENDS IN GLOBAL HEALTHCARE INDUSTRY   61

6.3           SUPPLY CHAIN ANALYSIS             62

6.3.1        PROMINENT COMPANIES            62

6.3.2        SMALL & MEDIUM-SIZED ENTERPRISES 62

6.3.3        END USERS         62

6.4           VALUE CHAIN ANALYSIS               63

6.4.1        RESEARCH & DEVELOPMENT    63

6.4.2        RAW MATERIAL PROCUREMENT               63

6.4.3        MANUFACTURING & ASSEMBLY                63

6.4.4        DISTRIBUTION, MARKETING & SALES, AND POST-SALE SERVICES             63

6.5           ECOSYSTEM ANALYSIS  64

6.6           PRICING ANALYSIS          64

6.7           TRADE ANALYSIS             67

6.7.1        TRADE DATA FOR COMPUTED TOMOGRAPHY SYSTEMS (HS CODE 902212)             67

6.7.1.1    Import data            67

6.7.1.2    Export data            68

6.7.2        TRADE ANALYSIS FOR ULTRASOUND SYSTEMS (HS CODE 901812)     69

6.7.2.1    Import data            69

6.7.2.2    Export data            70

6.7.3        TRADE ANALYSIS FOR MAGNETIC RESONANCE IMAGING SYSTEMS (HS CODE 901813)    71

6.7.3.1    Import data            71

6.7.3.2    Export data            72

6.7.4        TRADE ANALYSIS FOR X-RAY SYSTEMS (HS CODE 902214)  73

6.7.4.1    Import data            73

6.7.4.2    Export data            74

6.8           KEY CONFERENCES AND EVENTS, 2025–2026        75

6.9           TRENDS IMPACTING CUSTOMERS’ BUSINESSES                 76

6.10         INVESTMENT AND FUNDING SCENARIO               77

6.11         CASE STUDY ANALYSIS 78

6.12         IMPACT OF 2025 US TARIFF         79

6.12.1      INTRODUCTION              79

6.12.2      KEY TARIFF RATES          79

6.12.3      PRICE IMPACT ANALYSIS             80

6.12.4      IMPACT ON COUNTRY/REGION                80

6.12.4.1  US           80

6.12.4.2  Europe   80

6.12.4.3  Asia Pacific            81

6.12.5      IMPACT ON END-USE INDUSTRIES          81

7               STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION                82

7.1           KEY EMERGING TECHNOLOGIES              82

7.1.1        MAGNETIC RESONANCE IMAGING (MRI)              82

7.1.2        COMPUTED TOMOGRAPHY (CT)              82

7.1.3        ULTRASOUND IMAGING               82

7.2           COMPLEMENTARY TECHNOLOGIES       83

7.2.1        PICTURE ARCHIVING AND COMMUNICATION SYSTEMS (PACS)  83

7.2.2        ARTIFICIAL INTELLIGENCE (AI) FOR IMAGE ANALYSIS                 83

7.3           PATENT ANALYSIS          83

7.4           IMPACT OF AI ON VASCULAR IMAGING MARKET                 88

7.4.1        INTRODUCTION              88

7.4.2        TOP USE CASES AND MARKET POTENTIAL          88

7.4.3        BEST PRACTICES IN VASCULAR IMAGING MARKET                 89

7.4.4        CASE STUDY ON AI IMPLEMENTATION IN VASCULAR IMAGING MARKET           89

7.4.5        CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE VASCULAR IMAGING MARKET         90

7.5           SUCCESS STORIES AND REAL-WORLD APPLICATIONS                 90

8               REGULATORY LANDSCAPE         92

8.1           REGULATIONS AND COMPLIANCE          92

8.1.1        REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             92

8.1.1.1    North America      92

8.1.1.1.1 US           92

8.1.1.1.2 Canada   93

8.1.1.2    Europe   93

8.1.1.3    Asia Pacific            94

8.1.1.3.1 Japan      94

8.1.1.3.2 China      95

8.1.1.3.3 India       96

8.2           INDUSTRY STANDARDS                97

8.3           CUSTOMER LANDSCAPE AND BUYER BEHAVIOR                 97

8.3.1        DECISION-MAKING PROCESS     97

8.4           KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA             98

8.4.1        KEY STAKEHOLDERS IN BUYING PROCESS           98

8.4.2        BUYING CRITERIA           99

8.5           ADOPTION BARRIERS AND INTERNAL CHALLENGES                 100

8.6           UNMET NEEDS FROM VARIOUS END-USE CUSTOMERS                 100

9               VASCULAR IMAGING MARKET, BY PRODUCT TYPE                 101

9.1           INTRODUCTION              102

9.2           SYSTEMS & CONSOLES  102

9.2.1        ULTRASOUND  103

9.2.1.1    Duplex ultrasound                103

9.2.1.1.1 Ongoing shift toward non-invasive and radiation-free imaging techniques to drive market 103

9.2.1.2    Doppler ultrasound              104

9.2.1.2.1 Increasing prevalence of lifestyle-related conditions to propel market    104

9.2.2        MRI        105

9.2.2.1    Growing adoption of non-invasive diagnostic techniques to fuel market    105

9.2.3        X-RAY    106

9.2.3.1    High spatial resolution and real-time imaging ability to boost market    106

9.2.4        NUCLEAR IMAGING SYSTEMS    107

9.2.4.1    Increasing advancements in hybrid imaging systems to facilitate growth    107

9.2.5        CT SCANNERS   108

9.2.5.1    Wide applicability of CT in diagnosing vascular abnormalities to favor growth          108

9.2.6        OPTICAL COHERENCE TOMOGRAPHY  109

9.2.6.1    Ability to provide micron-level resolution to support growth                 109

9.2.7        OTHER SYSTEMS & CONSOLES  110

9.3           ACCESSORIES & CONSUMABLES                110

9.3.1        NEED FOR CONSISTENT IMAGE QUALITY AND PATIENT SAFETY TO FOSTER GROWTH   110

9.4           SOFTWARE & SERVICES 111

9.4.1        STRAIN IMAGING             111

9.4.1.1    Rising focus on early detection of vascular diseases to aid growth                 111

9.4.2        HIGH SPATIAL AND TEMPORAL RESOLUTION   112

9.4.2.1    Increasing product development to facilitate growth      112

9.4.3        AUTOMATED VESSEL MORPHOLOGY ASSESSMENT                 113

9.4.3.1    Need for precise and reproducible analysis to expedite growth                 113

9.4.4        STREAMLINED PROCEDURAL WORKFLOW          113

9.4.4.1    Rising patient volume to contribute to growth                 113

9.4.5        OTHER SOFTWARE & SERVICES 114

10            VASCULAR IMAGING MARKET, BY APPLICATION                 115

10.1         INTRODUCTION              116

10.2         ATHEROSCLEROSIS        116

10.2.1      GROWING GLOBAL BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET     116

10.3         ANEURYSM         117

10.3.1      EXPANDING ACCESS TO DIAGNOSTIC FACILITIES TO BOOST MARKET               117

10.4         VASCULITIS        118

10.4.1      GROWING INCIDENCE OF AUTOIMMUNE AND INFLAMMATORY DISORDERS TO PROPEL MARKET         118

10.5         DEEP VEIN THROMBOSIS             119

10.5.1      INCREASING FOCUS ON PREVENTIVE HEALTHCARE AND TECHNOLOGICAL INNOVATIONS TO PROMOTE GROWTH                 119

10.6         ARTERIOVENOUS MALFORMATIONS & FISTULAS                 119

10.6.1      RISING USE OF MINIMALLY INVASIVE ENDOVASCULAR THERAPIES TO EXPEDITE GROWTH        119

10.7         OTHER APPLICATIONS 120

11            VASCULAR IMAGING MARKET, BY END USER     121

11.1         INTRODUCTION              122

11.2         HOSPITALS         122

11.2.1      STRONG REIMBURSEMENT FRAMEWORKS AND GOVERNMENT SUPPORT FOR MODERNIZING HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET  122

11.3         DIAGNOSTIC IMAGING CENTERS             123

11.3.1      INCREASING FOCUS ON OUTPATIENT CARE AND PREVENTIVE DIAGNOSTICS TO ENCOURAGE GROWTH                 123

11.4         AMBULATORY SURGERY CENTERS          124

11.4.1      GROWING EMPHASIS ON VALUE-BASED CARE TO PROPEL MARKET             124

11.5         OTHER END USERS         125

12            VASCULAR IMAGING MARKET, BY REGION          127

12.1         INTRODUCTION              128

12.2         NORTH AMERICA             129

12.2.1      NORTH AMERICA: MACROECONOMIC OUTLOOK                 129

12.2.2      US           133

12.2.2.1  High prevalence of chronic vascular diseases to drive market                 133

12.2.3      CANADA               135

12.2.3.1  Rapidly aging population to support growth    135

12.3         EUROPE               137

12.3.1      EUROPE: MACROECONOMIC OUTLOOK               137

12.3.2      GERMANY           141

12.3.2.1  High number of MRI and CT units to fuel market          141

12.3.3      UK          142

12.3.3.1  Increasing investments in imaging infrastructure to drive market                 142

12.3.4      FRANCE                144

12.3.4.1  Increasing focus on early detection of vascular disorders and strong technological adoption to boost market                144

12.3.5      ITALY    145

12.3.5.1  Demographic shift toward aging population and increasing focus on non-invasive diagnostic solutions to aid growth         145

12.3.6      SPAIN    147

12.3.6.1  Growing access to advanced cancer vascular to propel market                 147

12.3.7      REST OF EUROPE             148

12.4         ASIA PACIFIC     150

12.4.1      ASIA PACIFIC: MACROECONOMIC OUTLOOK     150

12.4.2      JAPAN   155

12.4.2.1  Presence of universal healthcare coverage to fuel market                 155

12.4.3      CHINA  157

12.4.3.1  Favorable government initiatives and demographic shift to aid growth    157

12.4.4      INDIA    158

12.4.4.1  Increasing number of vascular procedures and public & private investments to promote growth          158

12.4.5      SOUTH KOREA  160

12.4.5.1  Growing awareness about diseases and rising applications of ultrasound to boost market 160

12.4.6      AUSTRALIA         162

12.4.6.1  Increasing healthcare spending to propel market            162

12.4.7      REST OF ASIA PACIFIC   164

12.5         LATIN AMERICA                165

12.5.1      LATIN AMERICA: MACROECONOMIC OUTLOOK                 165

12.5.2      BRAZIL 169

12.5.2.1  Favorable demographic conditions and coverage policies to propel market        169

12.5.3      MEXICO                171

12.5.3.1  Growing adoption of advanced diagnostic imaging systems to drive market          171

12.5.4      REST OF LATIN AMERICA             172

12.6         MIDDLE EAST & AFRICA                174

12.6.1      MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK                 174

12.6.2      GCC COUNTRIES              178

12.6.2.1  Increasing prevalence of cardiovascular diseases, diabetes, and hypertension to support growth         178

12.6.3      REST OF MIDDLE EAST & AFRICA             179

13            COMPETITIVE LANDSCAPE         182

13.1         INTRODUCTION              182

13.2         KEY PLAYER STRATEGY/RIGHT TO WIN                182

13.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VASCULAR IMAGING MARKET   183

13.3         REVENUE ANALYSIS, 2021–2024  184

13.4         MARKET SHARE ANALYSIS, 2024                 185

13.5         COMPANY VALUATION AND FINANCIAL METRICS                 187

13.6         BRAND/PRODUCT COMPARISON             188

13.7         COMPANY EVALUATION MATRIX: VASCULAR IMAGING MARKET, 2024    188

13.7.1      STARS   188

13.7.2      EMERGING LEADERS     188

13.7.3      PERVASIVE PLAYERS      189

13.7.4      PARTICIPANTS 189

13.7.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         190

13.7.5.1  Company footprint               190

13.7.5.2  Region footprint   190

13.7.5.3  Product footprint  191

13.7.5.4  Application footprint            193

13.7.5.5  End-user footprint                193

13.8         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        194

13.8.1      PROGRESSIVE COMPANIES         194

13.8.2      RESPONSIVE COMPANIES            194

13.8.3      DYNAMIC COMPANIES  195

13.8.4      STARTING BLOCKS         195

13.8.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 196

13.8.5.1  Detailed list of key startups/SMEs    196

13.8.5.2  Competitive benchmarking of key startups/SMEs          197

13.9         COMPETITIVE SCENARIO             198

13.9.1      PRODUCT LAUNCHES, UPGRADES, AND APPROVALS                 198

13.9.2      DEALS  199

13.9.3      EXPANSIONS     199

14            COMPANY PROFILES      201

14.1         KEY PLAYERS     201

14.1.1      SIEMENS HEALTHINEERS AG      201

14.1.1.1  Business overview 201

14.1.1.2  Products offered   202

14.1.1.3  Recent developments           203

14.1.1.3.1                Deals      203

14.1.1.3.2                Expansions             205

14.1.1.4  MnM view              205

14.1.1.4.1                Key strengths        205

14.1.1.4.2                Strategic choices   205

14.1.1.4.3                Weaknesses and competitive threats 205

14.1.2      GE HEALTHCARE             206

14.1.2.1  Business overview 206

14.1.2.2  Products offered   207

14.1.2.3  Recent developments           209

14.1.2.3.1                Product launches, upgrades, and approvals     209

14.1.2.3.2                Deals      210

14.1.2.3.3                Expansions             212

14.1.2.4  MnM view              212

14.1.2.4.1                Key strengths        212

14.1.2.4.2                Strategic choices   212

14.1.2.4.3                Weaknesses and competitive threats 212

14.1.3      FUJIFILM CORPORATION             213

14.1.3.1  Business overview 213

14.1.3.2  Products offered   214

14.1.3.3  Recent developments           216

14.1.3.3.1                Product launches, upgrades, and approvals     216

14.1.3.3.2                Deals      216

14.1.3.3.3                Expansions             217

14.1.3.4  MnM view              217

14.1.3.4.1                Key strengths        217

14.1.3.4.2                Strategic choices   217

14.1.3.4.3                Weaknesses and competitive threats.                217

14.1.4      PHILIPS HEALTHCARE  218

14.1.4.1  Business overview 218

14.1.4.2  Products offered   219

14.1.4.3  Recent developments           221

14.1.4.3.1                Product launches, upgrades, and approvals     221

14.1.4.3.2                Deals      221

14.1.4.3.3                Expansions             222

14.1.4.4  MnM view              223

14.1.4.4.1                Key strengths        223

14.1.4.4.2                Strategic choices   223

14.1.4.4.3                Weaknesses and competitive threats 223

14.1.5      SHIMADZU CORPORATION         224

14.1.5.1  Business overview 224

14.1.5.2  Products offered   225

14.1.5.3  Recent developments           226

14.1.5.3.1                Deals      226

14.1.6      UNITED IMAGING HEALTHCARE CO., LTD           227

14.1.6.1  Business overview 227

14.1.6.2  Products offered   228

14.1.6.3  Recent developments           229

14.1.6.3.1                Product launches, upgrades, and approvals     229

14.1.6.3.2                Deals      229

14.1.6.3.3                Expansions             230

14.1.7      SAMSUNG HEALTHCARE              231

14.1.7.1  Business overview 231

14.1.7.2  Products offered   232

14.1.7.3  Recent developments           233

14.1.7.3.1                Product launches, upgrades, and approvals     233

14.1.7.3.2                Deals      233

14.1.7.3.3                Other developments             233

14.1.8      SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.      234

14.1.8.1  Business overview 234

14.1.8.2  Products offered   235

14.1.8.3  Recent developments           235

14.1.8.3.1                Product launches, upgrades, and approvals     235

14.1.8.3.2                Deals      236

14.1.9      CANON MEDICAL SYSTEMS CORPORATION        237

14.1.9.1  Business overview 237

14.1.9.2  Products offered   238

14.1.9.3  Recent developments           239

14.1.9.3.1                Product launches, upgrades, and approvals     239

14.1.9.3.2                Deals      239

14.1.9.3.3                Expansions             240

14.1.10   KONICA MINOLTA, INC.                241

14.1.10.1                 Business overview 241

14.1.10.2                 Products offered   242

14.1.11   NEUSOFT CORPORATION            244

14.1.11.1                 Business overview 244

14.1.11.2                 Products offered   245

14.1.11.3                 Recent developments           246

14.1.11.3.1             Product launches, upgrades, and approvals     246

14.1.12   TERUMO CORPORATION             247

14.1.12.1                 Business overview 247

14.1.12.2                 Products offered   248

14.1.13   HOLOGIC, INC. 249

14.1.13.1                 Business overview 249

14.1.13.2                 Products offered   250

14.1.13.3                 Recent developments           251

14.1.13.3.1             Deals      251

14.1.13.3.2             Expansions             251

14.1.14   BRACCO IMAGING S.P.A.               252

14.1.14.1                 Business overview 252

14.1.14.2                 Products offered   252

14.1.14.3                 Recent developments           253

14.1.14.3.1             Deals      253

14.1.14.3.2             Expansions             253

14.1.15   BAYER AG            254

14.1.15.1                 Business overview 254

14.1.15.2                 Products offered   255

14.1.15.3                 Recent developments           256

14.1.15.3.1             Deals      256

14.1.15.3.2             Expansions             256

14.1.16   GUERBET            257

14.1.16.1                 Business overview 257

14.1.16.2                 Products offered   258

14.1.17   NIPRO EUROPE GROUP COMPANIES      259

14.1.17.1                 Business overview 259

14.1.17.2                 Products offered   259

14.2         OTHER PLAYERS              260

14.2.1      ACCUVEIN, INC.                260

14.2.2      CHISON MEDICAL TECHNOLOGIES CO., LTD.    261

14.2.3      SONOSCAPE MEDICAL CORP.    262

14.2.4      PIUR IMAGING  263

14.2.5      ARINETA LTD    263

14.2.6      HEALCERION CO., LTD. 264

14.2.7      ECHONOUS INC.               265

14.2.8      BEIJING WEMED MEDICAL EQUIPMENT                266

14.2.9      CLARIUS               267

14.2.10   ESAOTE SPA       268

15            APPENDIX           269

15.1         DISCUSSION GUIDE        269

15.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                272

15.3         CUSTOMIZATION OPTIONS        274

15.4         RELATED REPORTS         274

15.5         AUTHOR DETAILS           275

LIST OF TABLES

TABLE 1                VASCULAR IMAGING MARKET: INCLUSIONS AND EXCLUSIONS           27

TABLE 2                VASCULAR IMAGING MARKET: RISK ANALYSIS                 41

TABLE 3                TECHNOLOGICAL ADVANCEMENTS IN VASCULAR IMAGING SYSTEMS  50

TABLE 4                VASCULAR IMAGING MARKET: UNMET NEEDS                 56

TABLE 5                STRATEGIC MOVES BY KEY COMPANIES IN VASCULAR IMAGING MARKET   57

TABLE 6                VASCULAR IMAGING MARKET: PORTER’S FIVE FORCES ANALYSIS           59

TABLE 7                REGIONAL PRICING ANALYSIS OF KEY VASCULAR IMAGING MODALITIES,

2024 (USD)          65

TABLE 8                REGIONAL PRICING ANALYSIS OF KEY DIAGNOSTIC IMAGING MODALITIES,

2024 (USD)          66

TABLE 9                IMPORT DATA FOR COMPUTED TOMOGRAPHY SYSTEMS, 2020–2024 (HS CODE 902212)   68

TABLE 10              EXPORT DATA FOR COMPUTED TOMOGRAPHY SYSTEMS (HS CODE 902212),

BY COUNTRY, 2020–2024 (USD THOUSAND)         69

TABLE 11              IMPORT DATA FOR ULTRASOUND SYSTEMS (HS CODE 901812), BY COUNTRY,  2020–2024 (USD THOUSAND)                 70

TABLE 12              EXPORT DATA FOR ULTRASOUND SYSTEMS (HS CODE 901812), BY COUNTRY,  2020–2024 (USD THOUSAND)                 71

TABLE 13              IMPORT DATA FOR MAGNETIC RESONANCE IMAGING SYSTEMS (HS CODE 901813),  BY COUNTRY, 2020–2024 (USD THOUSAND)           72

TABLE 14              EXPORT DATA FOR MAGNETIC RESONANCE IMAGING SYSTEMS (HS CODE 901813),  BY COUNTRY, 2020–2024 (USD THOUSAND)           73

TABLE 15              IMPORT DATA FOR X-RAY SYSTEMS (HS CODE 902214), BY COUNTRY,

2020–2024 (USD THOUSAND)      74

TABLE 16              EXPORT DATA FOR X-RAY SYSTEMS (HS CODE 902214), BY COUNTRY,

2020–2024 (USD THOUSAND)      75

TABLE 17              VASCULAR IMAGING MARKET: KEY CONFERENCES AND EVENTS, 2025–2026                 75

TABLE 18              CASE STUDY: MAINTAINING STRONG FOCUS ON TECHNOLOGICAL INNOVATION AND ADDRESSING REGULATORY COMPLIANCE      78

TABLE 19              US ADJUSTED RECIPROCAL TARIFF RATES                 79

TABLE 20              CASE STUDY: AI-ASSISTED INTRAVASCULAR IMAGING FOR PRECISION ANGIOPLASTY             89

TABLE 21              INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS        90

TABLE 22              US FDA: MEDICAL DEVICE CLASSIFICATION                 92

TABLE 23              US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS              93

TABLE 24              CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS      93

TABLE 25              JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA   94

TABLE 26              CHINA: CLASSIFICATION OF MEDICAL DEVICES                 95

TABLE 27              INDUSTRY STANDARDS FOR VASCULAR IMAGING MARKET           97

TABLE 28              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)        98

TABLE 29              KEY BUYING CRITERIA, BY END USER    99

TABLE 30              VASCULAR IMAGING MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)                102

TABLE 31              VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY REGION,

2023–2030 (USD MILLION)          102

TABLE 32              VASCULAR IMAGING MARKET FOR ULTRASOUND, BY REGION,

2023–2030 (USD MILLION)            103

TABLE 33              VASCULAR IMAGING MARKET FOR DUPLEX ULTRASOUND, BY REGION,

2023–2030 (USD MILLION)          104

TABLE 34              VASCULAR IMAGING MARKET FOR DOPPLER ULTRASOUND, BY REGION,

2023–2030 (USD MILLION)            105

TABLE 35              VASCULAR IMAGING MARKET FOR MRI, BY REGION, 2023–2030 (USD MILLION)          106

TABLE 36              VASCULAR IMAGING MARKET FOR X-RAY SYSTEMS, BY REGION,

2023–2030 (USD MILLION)            107

TABLE 37              VASCULAR IMAGING MARKET FOR NUCLEAR IMAGING SYSTEMS, BY REGION,  2023–2030 (USD MILLION)                 108

TABLE 38              VASCULAR IMAGING MARKET FOR CT SCANNERS, BY REGION,

2023–2030 (USD MILLION)            109

TABLE 39              VASCULAR IMAGING MARKET FOR OPTICAL COHERENCE TOMOGRAPHY,

BY REGION, 2023–2030 (USD MILLION)   109

TABLE 40              VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY REGION,

2023–2030 (USD MILLION)            110

TABLE 41              VASCULAR IMAGING MARKET FOR ACCESSORIES & CONSUMABLES, BY REGION,  2023–2030 (USD MILLION)            111

TABLE 42              VASCULAR IMAGING MARKET FOR STRAIN IMAGING, BY REGION,

2023–2030 (USD MILLION)            112

TABLE 43              VASCULAR IMAGING MARKET FOR HIGH SPATIAL AND TEMPORAL RESOLUTION,  BY REGION, 2023–2030 (USD MILLION)       112

TABLE 44              VASCULAR IMAGING MARKET FOR AUTOMATED VESSEL MORPHOLOGY ASSESSMENT,  BY REGION, 2023–2030 (USD MILLION)          113

TABLE 45              VASCULAR IMAGING MARKET FOR STREAMLINED PROCEDURAL WORKFLOW,

BY REGION, 2023–2030 (USD MILLION)   114

TABLE 46              VASCULAR IMAGING MARKET FOR OTHER SOFTWARE & SERVICES, BY REGION,  2023–2030 (USD MILLION)                 114

TABLE 47              VASCULAR IMAGING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              116

TABLE 48              VASCULAR IMAGING MARKET FOR ATHEROSCLEROSIS, BY REGION,

2023–2030 (USD MILLION)            117

TABLE 49              VASCULAR IMAGING MARKET FOR ANEURYSM, BY REGION,

2023–2030 (USD MILLION)            118

TABLE 50              VASCULAR IMAGING MARKET FOR VASCULITIS, BY REGION,

2023–2030 (USD MILLION)            118

TABLE 51              VASCULAR IMAGING MARKET FOR DEEP VEIN THROMBOSIS, BY REGION,

2023–2030 (USD MILLION)            119

TABLE 52              VASCULAR IMAGING MARKET FOR ARTERIOVENOUS MALFORMATIONS & FISTULAS,  BY REGION, 2023–2030 (USD MILLION)            120

TABLE 53              VASCULAR IMAGING MARKET FOR OTHER APPLICATIONS, BY REGION,

2023–2030 (USD MILLION)            120

TABLE 54              VASCULAR IMAGING MARKET, BY END USER, BY TYPE, 2023–2030 (USD MILLION)                122

TABLE 55              VASCULAR IMAGING MARKET FOR HOSPITALS, BY REGION,

2023–2030 (USD MILLION)            123

TABLE 56              VASCULAR IMAGING MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION,  2023–2030 (USD MILLION)            124

TABLE 57              VASCULAR IMAGING MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION,  2023–2030 (USD MILLION) 125

TABLE 58              VASCULAR IMAGING MARKET FOR OTHER END USERS, BY REGION,

2023–2030 (USD MILLION)            126

TABLE 59              VASCULAR IMAGING MARKET, BY REGION, 2023–2030 (USD MILLION)            128

TABLE 60              NUMBER OF IMAGING TESTS IN UK, 2022–2025                 128

TABLE 61              NUMBER OF MRI UNITS PER COUNTRY, 2022–2024        129

TABLE 62              NORTH AMERICA: MACROECONOMIC OUTLOOK           130

TABLE 63              NORTH AMERICA: VASCULAR IMAGING MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            131

TABLE 64              NORTH AMERICA: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            131

TABLE 65              NORTH AMERICA: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES,

BY TYPE,  2023–2030 (USD MILLION)      131

TABLE 66              NORTH AMERICA: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,  2023–2030 (USD MILLION)            132

TABLE 67              NORTH AMERICA: VASCULAR IMAGING MARKET FOR SOFTWARE & SERVICES,

BY TYPE,  2023–2030 (USD MILLION)      132

TABLE 68              NORTH AMERICA: VASCULAR IMAGING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            133

TABLE 69              NORTH AMERICA: VASCULAR IMAGING MARKET, BY END USER,

2023–2030 (USD MILLION)            133

TABLE 70              US: VASCULAR IMAGING MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)         134

TABLE 71              US: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,

2023–2030 (USD MILLION)            135

TABLE 72              US: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            135

TABLE 73              CANADA: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            136

TABLE 74              CANADA: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,  2023–2030 (USD MILLION)                 136

TABLE 75              CANADA: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            137

TABLE 76              EUROPE: MACROECONOMIC OUTLOOK                 138

TABLE 77              EUROPE: VASCULAR IMAGING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     138

TABLE 78              EUROPE: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            139

TABLE 79              EUROPE: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,  2023–2030 (USD MILLION)                 139

TABLE 80              EUROPE: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            139

TABLE 81              EUROPE: VASCULAR IMAGING MARKET FOR SOFTWARE & SERVICES, BY TYPE,  2023–2030 (USD MILLION)                 140

TABLE 82              EUROPE: VASCULAR IMAGING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            140

TABLE 83              EUROPE: VASCULAR IMAGING MARKET, BY END USER, 2023–2030 (USD MILLION)                141

TABLE 84              GERMANY: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            141

TABLE 85              GERMANY: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,  2023–2030 (USD MILLION)                 142

TABLE 86              GERMANY: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            142

TABLE 87              UK: VASCULAR IMAGING MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)         143

TABLE 88              UK: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,

2023–2030 (USD MILLION)            143

TABLE 89              UK: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            144

TABLE 90              FRANCE: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            144

TABLE 91              FRANCE: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,  2023–2030 (USD MILLION)                 145

TABLE 92              FRANCE: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            145

TABLE 93              ITALY: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            146

TABLE 94              ITALY: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,

2023–2030 (USD MILLION)            146

TABLE 95              ITALY: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            147

TABLE 96              SPAIN: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            147

TABLE 97              SPAIN: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,  2023–2030 (USD MILLION)                 148

TABLE 98              SPAIN: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            148

TABLE 99              REST OF EUROPE: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            149

TABLE 100            REST OF EUROPE: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES,

BY TYPE,  2023–2030 (USD MILLION)      149

TABLE 101            REST OF EUROPE: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,  2023–2030 (USD MILLION)            149

TABLE 102            ASIA PACIFIC: MACROECONOMIC INDICATORS                 151

TABLE 103            ASIA PACIFIC: VASCULAR IMAGING MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 104            ASIA PACIFIC: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            152

TABLE 105            ASIA PACIFIC: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,  2023–2030 (USD MILLION)            153

TABLE 106            ASIA PACIFIC: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            153

TABLE 107            ASIA PACIFIC: VASCULAR IMAGING MARKET FOR SOFTWARE & SERVICES, BY TYPE,  2023–2030 (USD MILLION)            154

TABLE 108            ASIA PACIFIC: VASCULAR IMAGING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            154

TABLE 109            ASIA PACIFIC: VASCULAR IMAGING MARKET, BY END USER,

2023–2030 (USD MILLION)            155

TABLE 110            JAPAN: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            156

TABLE 111            JAPAN: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,  2023–2030 (USD MILLION)                 156

TABLE 112            JAPAN: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            156

TABLE 113            CHINA: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            157

TABLE 114            CHINA: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,  2023–2030 (USD MILLION)                 158

TABLE 115            CHINA: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            158

TABLE 116            INDIA: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            159

TABLE 117            INDIA: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,

2023–2030 (USD MILLION)            160

TABLE 118            INDIA: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            160

TABLE 119            SOUTH KOREA: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            161

TABLE 120            SOUTH KOREA: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES,

BY TYPE, 2023–2030 (USD MILLION)         161

TABLE 121            SOUTH KOREA: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            162

TABLE 122            AUSTRALIA: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            163

TABLE 123            AUSTRALIA: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,  2023–2030 (USD MILLION)                 163

TABLE 124            AUSTRALIA: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            163

TABLE 125            REST OF ASIA PACIFIC: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            164

TABLE 126            REST OF ASIA PACIFIC: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES,  BY TYPE, 2023–2030 (USD MILLION)            165

TABLE 127            REST OF ASIA PACIFIC: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,  2023–2030 (USD MILLION)            165

TABLE 128            LATIN AMERICA: MACROECONOMIC OUTLOOK                 166

TABLE 129            LATIN AMERICA: VASCULAR IMAGING MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            167

TABLE 130            LATIN AMERICA: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            167

TABLE 131            LATIN AMERICA: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES,

BY TYPE,  2023–2030 (USD MILLION)      167

TABLE 132            LATIN AMERICA: ULTRASOUND MARKET, BY TYPE, 2023–2030 (USD MILLION)                168

TABLE 133            LATIN AMERICA: VASCULAR IMAGING MARKET FOR SOFTWARE & SERVICES,

BY TYPE,  2023–2030 (USD MILLION)      168

TABLE 134            LATIN AMERICA: VASCULAR IMAGING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            168

TABLE 135            LATIN AMERICA: VASCULAR IMAGING MARKET, BY END USER,

2023–2030 (USD MILLION)            169

TABLE 136            BRAZIL: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            170

TABLE 137            BRAZIL: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,  2023–2030 (USD MILLION)                 170

TABLE 138            BRAZIL: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            170

TABLE 139            MEXICO: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            171

TABLE 140            MEXICO: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES, BY TYPE,  2023–2030 (USD MILLION)                 172

TABLE 141            MEXICO: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,

2023–2030 (USD MILLION)            172

TABLE 142            REST OF LATIN AMERICA: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,  2023–2030 (USD MILLION)                 173

TABLE 143            REST OF LATIN AMERICA: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES,  BY TYPE, 2023–2030 (USD MILLION)            173

TABLE 144            REST OF LATIN AMERICA: VASCULAR IMAGING MARKET FOR ULTRASOUND,

BY TYPE,  2023–2030 (USD MILLION)      173

TABLE 145            MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK           175

TABLE 146            MIDDLE EAST & AFRICA: VASCULAR IMAGING MARKET, BY REGION,

2023–2030 (USD MILLION)            175

TABLE 147            MIDDLE EAST & AFRICA: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            175

TABLE 148            MIDDLE EAST & AFRICA: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES,  BY TYPE, 2023–2030 (USD MILLION)            176

TABLE 149            MIDDLE EAST & AFRICA: VASCULAR IMAGING MARKET FOR ULTRASOUND,

BY TYPE,  2023–2030 (USD MILLION)      176

TABLE 150            MIDDLE EAST & AFRICA: VASCULAR IMAGING MARKET FOR SOFTWARE & SERVICES,  BY TYPE, 2023–2030 (USD MILLION) 177

TABLE 151            MIDDLE EAST & AFRICA: VASCULAR IMAGING MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            177

TABLE 152            MIDDLE EAST & AFRICA: VASCULAR IMAGING MARKET, BY END USER,

2023–2030 (USD MILLION)            178

TABLE 153          GCC COUNTRIES: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            178

TABLE 154            GCC COUNTRIES: VASCULAR IMAGING MARKET FOR SYSTEMS & CONSOLES MARKET,  BY TYPE, 2023–2030 (USD MILLION)            179

TABLE 155            GCC COUNTRIES: VASCULAR IMAGING MARKET FOR ULTRASOUND, BY TYPE,  2023–2030 (USD MILLION)                 179

TABLE 156            REST OF MIDDLE EAST & AFRICA: VASCULAR IMAGING MARKET, BY PRODUCT TYPE,  2023–2030 (USD MILLION)            180

TABLE 157            REST OF MIDDLE EAST & AFRICA: SYSTEMS AND CONSOLES MARKET, BY TYPE,  2023–2030 (USD MILLION)                 180

TABLE 158            REST OF MIDDLE EAST & AFRICA: ULTRASOUND MARKET, BY TYPE,

2023–2030 (USD MILLION)            181

TABLE 159            OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN VASCULAR IMAGING MARKET, JANUARY 2022–OCTOBER 2025  183

TABLE 160            VASCULAR IMAGING MARKET: DEGREE OF COMPETITION 185

TABLE 161            VASCULAR IMAGING MARKET: REGION FOOTPRINT       190

TABLE 162            VASCULAR IMAGING MARKET: PRODUCT TYPE FOOTPRINT (1/2)             191

TABLE 163            VASCULAR IMAGING MARKET: PRODUCT TYPE FOOTPRINT (2/2)             192

TABLE 164            VASCULAR IMAGING MARKET: APPLICATION FOOTPRINT       193

TABLE 165            VASCULAR IMAGING MARKET: END-USER FOOTPRINT       193

TABLE 166            VASCULAR IMAGING MARKET: DETAILED LIST OF KEY STARTUPS/SMES              196

TABLE 167            VASCULAR IMAGING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY REGION 197

TABLE 168            VASCULAR IMAGING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT TYPE                 197

TABLE 169            VASCULAR IMAGING MARKET: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022–AUGUST 2025     198

TABLE 170            VASCULAR IMAGING MARKET: DEALS, JANUARY 2022–AUGUST 2025           199

TABLE 171            VASCULAR IMAGING MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025       199

TABLE 172            SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW          201

TABLE 173            SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED             202

TABLE 174            SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–AUGUST 2025           203

TABLE 175            SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022–AUGUST 2025       205

TABLE 176            GE HEALTHCARE: COMPANY OVERVIEW                 206

TABLE 177            GE HEALTHCARE: PRODUCTS OFFERED                 207

TABLE 178            GE HEALTHCARE: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS,

JANUARY 2022–AUGUST 2025       209

TABLE 179            GE HEALTHCARE: DEALS, JANUARY 2022–AUGUST 2025     210

TABLE 180            GE HEALTHCARE: EXPANSIONS, JANUARY 2022–AUGUST 2025     212

TABLE 181            FUJIFILM CORPORATION: COMPANY OVERVIEW          213

TABLE 182            FUJIFILM CORPORATION: PRODUCTS OFFERED                 214

TABLE 183            FUJIFILM CORPORATION: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022–AUGUST 2025     216

TABLE 184            FUJIFILM CORPORATION: DEALS, JANUARY 2022–AUGUST 2025           216

TABLE 185            FUJIFILM CORPORATION: EXPANSIONS, JANUARY 2022–AUGUST 2025       217

TABLE 186            PHILIPS HEALTHCARE: COMPANY OVERVIEW                 218

TABLE 187            PHILIPS HEALTHCARE: PRODUCTS OFFERED                 219

TABLE 188            PHILIPS HEALTHCARE: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022–AUGUST 2025                 221

TABLE 189            PHILIPS HEALTHCARE: DEALS, JANUARY 2022–AUGUST 2025     221

TABLE 190            PHILIPS HEALTHCARE: EXPANSIONS, JANUARY 2022–AUGUST 2025           222

TABLE 191            SHIMADZU CORPORATION: COMPANY OVERVIEW          224

TABLE 192            SHIMADZU CORPORATION: PRODUCTS OFFERED             225

TABLE 193            SHIMADZU CORPORATION: DEALS, JANUARY 2022–AUGUST 2025           226

TABLE 194            UNITED IMAGING HEALTHCARE CO., LTD: COMPANY OVERVIEW   227

TABLE 195            UNITED IMAGING HEALTHCARE CO., LTD: PRODUCTS OFFERED    228

TABLE 196            UNITED IMAGING HEALTHCARE CO., LTD: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022–AUGUST 2025           229

TABLE 197            UNITED IMAGING HEALTHCARE CO., LTD: DEALS, JANUARY 2022–AUGUST 2025       229

TABLE 198            UNITED IMAGING HEALTHCARE CO., LTD: EXPANSIONS,

JANUARY 2022–AUGUST 2025       230

TABLE 199            SAMSUNG HEALTHCARE: COMPANY OVERVIEW                 231

TABLE 200            SAMSUNG HEALTHCARE: PRODUCTS OFFERED                 232

TABLE 201          SAMSUNG HEALTHCARE: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022–AUGUST 2025                 233

TABLE 202            SAMSUNG HEALTHCARE: DEALS, JANUARY 2022–AUGUST 2025           233

TABLE 203            SAMSUNG HEALTHCARE: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025  233

TABLE 204            SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW               234

TABLE 205            SHEZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 235

TABLE 206            SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022–AUGUST 2025 235

TABLE 207            SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: DEALS,  JANUARY 2022–AUGUST 2025                 236

TABLE 208            CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW   237

TABLE 209            CANON MEDICAL SYSTEMS CORPORATION: PRODUCTS OFFERED    238

TABLE 210            CANON MEDICAL SYSTEMS CORPORATION: PRODUCT LAUNCHES, UPGRADES,

AND APPROVALS, JANUARY 2022–AUGUST 2025 239

TABLE 211            CANON MEDICAL SYSTEMS CORPORATION: DEALS, JANUARY 2022–AUGUST 2025       239

TABLE 212            CANON MEDICAL SYSTEMS CORPORATION: EXPANSIONS,

JANUARY 2022–AUGUST 2025       240

TABLE 213            KONICA MINOLTA, INC.: COMPANY OVERVIEW                 241

TABLE 214            KONICA MINOLTA, INC.: PRODUCTS OFFERED                 242

TABLE 215            NEUSOFT CORPORATION: COMPANY OVERVIEW          244

TABLE 216            NEUSOFT CORPORATION: PRODUCTS OFFERED             245

TABLE 217            NEUSOFT CORPORATION: PRODUCT LAUNCHES, UPGRADES, AND APPROVALS, JANUARY 2022–AUGUST 2024     246

TABLE 218            TERUMO CORPORATION: COMPANY OVERVIEW          247

TABLE 219            TERUMO CORPORATION: PRODUCTS OFFERED                 248

TABLE 220            HOLOGIC, INC.: COMPANY OVERVIEW  249

TABLE 221            HOLOGIC, INC.: PRODUCTS OFFERED   250

TABLE 222            HOLOGIC, INC.: DEALS, JANUARY 2022–AUGUST 2025        251

TABLE 223            HOLOGIC, INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025     251

TABLE 224            BRACCO IMAGING S.P.A.: COMPANY OVERVIEW                 252

TABLE 225            BRACCO IMAGING S.P.A.: PRODUCTS OFFERED                 252

TABLE 226            BRACCO IMAGING S.P.A.: DEALS, JANUARY 2022–AUGUST 2025     253

TABLE 227            BRACCO IMAGING S.P.A.: EXPANSIONS, JANUARY 2022–AUGUST 2025       253

TABLE 228            BAYER AG: COMPANY OVERVIEW             254

TABLE 229            BAYER AG: PRODUCTS OFFERED              255

TABLE 230            BAYER AG: DEALS, JANUARY 2022–AUGUST 2025                 256

TABLE 231            BAYER AG: EXPANSION, JANUARY 2022–AUGUST 2025        256

TABLE 232            GUERBET: COMPANY OVERVIEW             257

TABLE 233            GUERBET: PRODUCTS OFFERED              258

TABLE 234            NIPRO EUROPE GROUP COMPANIES: COMPANY OVERVIEW          259

TABLE 235            NIPRO EUROPE GROUP COMPANIES: PRODUCTS OFFERED    259

TABLE 236            ACCUVEIN, INC.: COMPANY OVERVIEW 260

TABLE 237            CHISON MEDICAL TECHNOLOGIES CO., LTD.: COMPANY OVERVIEW   261

TABLE 238            SONOSCAPE MEDICAL CORP.: COMPANY OVERVIEW          262

TABLE 239            PIUR IMAGING: COMPANY OVERVIEW  263

TABLE 240            ARINETA LTD: COMPANY OVERVIEW    263

TABLE 241            HEALCERION CO., LTD.: COMPANY OVERVIEW                 264

TABLE 242            ECHONOUS INC.: COMPANY OVERVIEW                 265

TABLE 243            BEIJING WEMED MEDICAL EQUIPMENT: COMPANY OVERVIEW   266

TABLE 244            CLARIUS: COMPANY OVERVIEW               267

TABLE 245            ESAOTE SPA: COMPANY OVERVIEW        268

LIST OF FIGURES

FIGURE 1              VASCULAR IMAGING MARKET SEGMENTATION AND REGIONAL SCOPE 27

FIGURE 2              RESEARCH DESIGN         29

FIGURE 3              KEY SECONDARY SOURCES         30

FIGURE 4              PRIMARY SOURCES         32

FIGURE 5              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,

AND REGION     33

FIGURE 6              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS            34

FIGURE 7              RESEARCH METHODOLOGY: HYPOTHESIS BUILDING           35

FIGURE 8              MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)       36

FIGURE 9              MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH         37

FIGURE 10            TOP-DOWN APPROACH                38

FIGURE 11            GLOBAL MARKET GROWTH PROJECTIONS                 39

FIGURE 12            DATA TRIANGULATION METHODOLOGY                 40

FIGURE 13            VASCULAR IMAGING MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)      42

FIGURE 14            VASCULAR IMAGING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)       43

FIGURE 15            VASCULAR IMAGING MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)      43

FIGURE 16            GROWING PREVALENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET     45

FIGURE 17            HOSPITALS SEGMENT AND US LED NORTH AMERICAN MARKET IN 2025        46

FIGURE 18            CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD       47

FIGURE 19            VASCULAR IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES          48

FIGURE 20            VASCULAR IMAGING MARKET: PORTER’S FIVE FORCES                59

FIGURE 21            VASCULAR IMAGING MARKET: SUPPLY CHAIN ANALYSIS            62

FIGURE 22            VASCULAR IMAGING MARKET: VALUE CHAIN ANALYSIS            63

FIGURE 23            ECOSYSTEM ANALYSIS  64

FIGURE 24            IMPORT SCENARIO FOR COMPUTED TOMOGRAPHY SYSTEMS (HS CODE 902212), 2020–2024 (USD THOUSAND)      67

FIGURE 25            EXPORT SCENARIO FOR COMPUTED TOMOGRAPHY SYSTEMS (HS CODE 902212), 2020–2024 (USD THOUSAND)      68

FIGURE 26            IMPORT SCENARIO FOR ULTRASOUND SYSTEMS (HS CODE 901812),

2020–2024 (USD THOUSAND)      69

FIGURE 27            EXPORT SCENARIO FOR ULTRASOUND SYSTEMS (HS CODE 901812),

2020–2024 (USD THOUSAND)      70

FIGURE 28            IMPORT SCENARIO FOR MAGNETIC RESONANCE IMAGING SYSTEMS

(HS CODE 901813), 2020–2024 (USD THOUSAND)                71

FIGURE 29            EXPORT SCENARIO FOR MAGNETIC RESONANCE IMAGING SYSTEMS

(HS CODE 901813), 2020–2024 (USD THOUSAND)                72

FIGURE 30            IMPORT SCENARIO FOR X-RAY SYSTEMS (HS CODE 902214),

2020–2024 (USD THOUSAND)      73

FIGURE 31            EXPORT SCENARIO FOR X-RAY SYSTEMS (HS CODE 902214),

2020–2024 (USD THOUSAND)      74

FIGURE 32            VASCULAR IMAGING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES                 77

FIGURE 33            INVESTMENT AND FUNDING SCENARIO, 2019–2023        77

FIGURE 34            NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023              78

FIGURE 35            VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 (USD MILLION)            78

FIGURE 36            TOP 10 PATENT APPLICANTS FOR CT SCANNERS,

JANUARY 2015–NOVEMBER 2025                 84

FIGURE 37           TOP 10 PATENT APPLICANTS FOR MRI SYSTEMS,

JANUARY 2015–NOVEMBER 2025                 85

FIGURE 38            TOP 10 PATENT APPLICANTS FOR ULTRASOUND IMAGING SYSTEMS,

JANUARY 2015– NOVEMBER 2025                86

FIGURE 39            TOP 10 PATENT APPLICANTS FOR X-RAY IMAGING SYSTEMS,

JANUARY 2015– NOVEMBER 2025                87

FIGURE 40            TOP 10 PATENT APPLICANTS FOR NUCLEAR IMAGING SYSTEMS,

JANUARY 2015–DECEMBER 2025 88

FIGURE 41            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS     98

FIGURE 42            KEY BUYING CRITERIA, BY END USER    99

FIGURE 43            NORTH AMERICA: VASCULAR IMAGING MARKET SNAPSHOT       130

FIGURE 44            ASIA PACIFIC: VASCULAR IMAGING MARKET SNAPSHOT          151

FIGURE 45            REVENUE ANALYSIS OF KEY PLAYERS IN VASCULAR IMAGING MARKET,

2021–2024 (USD BILLION)             184

FIGURE 46            MARKET SHARE ANALYSIS OF KEY PLAYERS IN VASCULAR IMAGING

MARKET, 2024    185

FIGURE 47            RANKING OF KEY PLAYERS IN VASCULAR IMAGING MARKET, 2024                186

FIGURE 48            EV/EBITDA OF KEY VENDORS   187

FIGURE 49            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF

KEY VENDORS 187

FIGURE 50            VASCULAR IMAGING MARKET: BRAND/PRODUCT COMPARISON             188

FIGURE 51            VASCULAR IMAGING MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       189

FIGURE 52            VASCULAR IMAGING MARKET: COMPANY FOOTPRINT       190

FIGURE 53            VASCULAR IMAGING MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2024                195

FIGURE 54            SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)             202

FIGURE 55            GE HEALTHCARE: COMPANY SNAPSHOT (2024)                 207

FIGURE 56            FUJIFILM CORPORATION: COMPANY SNAPSHOT (2024)             214

FIGURE 57            PHILIPS HEALTHCARE: COMPANY SNAPSHOT (2024)    219

FIGURE 58            SHIMADZU CORPORATION: COMPANY SNAPSHOT (2024)             225

FIGURE 59            UNITED IMAGING HEALTHCARE CO., LTD: COMPANY SNAPSHOT (2024)      227

FIGURE 60            SAMSUNG HEALTHCARE: COMPANY SNAPSHOT (2024)    232

FIGURE 61            SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.:

COMPANY SNAPSHOT (2023)      234

FIGURE 62            CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2024)      238

FIGURE 63            KONICA MINOLTA, INC.: COMPANY SNAPSHOT (2024)    242

FIGURE 64            NEUSOFT CORPORATION: COMPANY SNAPSHOT (2024)             244

FIGURE 65            TERUMO CORPORATION: COMPANY SNAPSHOT (2024)             248

FIGURE 66            HOLOGIC, INC.: COMPANY SNAPSHOT (2023)                 250

FIGURE 67            BAYER AG: COMPANY SNAPSHOT (2024)                 255

FIGURE 68            GUERBET: COMPANY SNAPSHOT (2022)                 257

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11
• 鉄道試験市場規模、シェア、動向、2032年までの世界予測 2025-12-10

MarketsandMarkets  出版レポート一覧